

M

EDCO FORUM®

PRESENTING INNOVATIVE PRODUCTS & SERVICES TO HEALTHCARE PROFESSIONALS

VOLUME 13 NUMBER 23

MAY 2006

REPRINT

CENTOCOR PIONEERS THE FUTURE OF BIOMEDICINES IN A YEAR IT BIDS FAREWELL TO THE CREATOR OF ITS ILLUSTRIOUS PAST

In 1979, Hubert Schoemaker captured the world's attention when he founded Centocor (Horsham, PA), at the age of 29, only halfway through a life that has been described as mythical in its proportions.



For the more than 25 years since then, the Immunology Pioneers at Centocor have been researching and developing innovative biomedicines that target immune-related diseases. Its research involving living proteins led the way in discovering unique biomedicines that can improve the lives of patients with disabling immune-mediated inflammatory disorders (I.M.I.D).

A High Unmet Medical Need

Though populations are comparatively small, I.M.I.D. patients suffer severe, debilitating symptoms. Ulcerative colitis (UC), for example, is a debilitating chronic disease affecting more than 500,000 Americans, for whom there is no medical cure, and while UC affects more people in the United States than multiple sclerosis or

cystic fibrosis, general awareness of the disease is lower. Characterized by inflammation and ulceration of the inner lining of the colon, UC symptoms can often include unwanted weight loss, severe—sometimes uncontrollable—bloody diarrhea, fatigue, and frequent abdominal pain. For some patients, symptoms may lead to surgical removal of the colon or to secondary complications such as colorectal cancer.

Biologics fill a gap in an area of high unmet medical need. Many I.M.I.D. patients have experienced only partial responses, or no response, to other available therapies. Drug side effects, drug delivery, and patient convenience provide further obstacles.

I.M.I.D. treatment often means more than just a reduction in immediate signs and symptoms. From reduced hospitalizations to increased workforce participation, greater comfort to increased mobility, biologics can dramatically improve a person's health and overall quality of life. By working together and sharing knowledge, we can achieve the one goal that remains consistent across the healthcare industry: getting the right treatment to the right person. Currently, only one company, Centocor, offers I.M.I.D. treatment in the gastrointestinal category. **REMICADE®** was the first and only biologic treatment approved for the treatment of Crohn's disease and Ulcerative colitis.

Leading the Way in Gastroenterology

In 1998, REMICADE (infliximab) was first approved for the treatment of Crohn's disease. Today, 280,000 Crohn's patients later, REMICADE remains the first and only biologic for treating both Crohn's disease and UC. With ten label indications in five disease states (Crohn's disease, rheumatoid arthritis, UC, ankylosing spondylitis, and psoriatic arthritis), REMICADE is approved in 84 countries and has been used to treat approximately 770,000 patients worldwide.

Centocor commitment to treating immune-related diseases includes innovative support for physicians and patients. The Centocor support system, "AccessOnesm" (www.centocoraccessone.com) presents options for establishing in-office infusion capability for REMICADE. Benefits to physicians include control of dosing, monitoring, scheduling and patient progress, and improved patient compliance by regularly scheduled appointments. Patients can locate access to infusion therapy via www.2infuse.com

and find valuable product and disease-specific information on other Centocor-sponsored web sites: www.REMICADE.com; www.livingWithCrohnsDisease.com; www.livingWithUC.com.


Pioneering the Future

Centocor R&D pioneers continue to work toward their goal of developing additional cures for immune-related diseases. Centocor has more R&D people than sales representatives and more people making REMICADE than selling it.

Centocor research pioneers have discovered that the cause of one immune system disease could be a common element of many diseases.

Currently, Centocor researchers are developing 13 compounds, studying 11 new indications for existing biomedicines, and conducting 25 research projects studying key molecular targets. With cutting-edge research and unyielding commitment, Centocor intends to maintain its leadership by pioneering the future of Gastroenterology.

As Centocor writes the future of immune-mediated inflammatory disorders, it closes a chapter of its illustrious history. After battling with cancer since 1994, Dr. Schoemaker died this New Year's Day, a day that poignantly reflects his love for new beginnings. Today, his vision, curiosity, and enthusiasm and optimism form the bedrock of the company determined to live out his dream of someday delivering cures.

Centocor is headquartered in Horsham, Pennsylvania, with facilities throughout the U.S. and Europe. Centocor employs more than 4,000 people involved in research & development, manufacturing, and marketing. In addition to REMICADE, Centocor developed and produces **ReoPro[®]** (abciximab), for treating complications of cardiac ischemia. 



For more information concerning Centocor Inc. call 1-610-651-6000, or visit the company's Web site at www.centocor.com.